Buscar
LifeVantage Corp
LFVNAñadir a la lista de seguimiento
6.220USD
-0.030-0.48%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
78.43MCap. mercado
13.50P/E TTM
Más Datos de LifeVantage Corp Compañía
LifeVantage Corporation is an activation company, which is engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. The Company’s line of scientifically validated activators includes the flagship Protandim family of products, TrueScience Liquid Collagen, the newest MindBody GLP-1 System, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System , as well as AXIO nootropic energy drink mixes, the full TrueScience line of skin and hair care products, and Petandim, a pet supplement formulated to combat oxidative stress in dogs. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore.
Información de LifeVantage Corp
Símbolo de cotizaciónLFVN
Nombre de la empresaLifeVantage Corp
Fecha de salida a bolsaSep 12, 2012
Director ejecutivoFife (Steven R)
Número de empleados232
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 12
Dirección3300 Triumph Blvd
CiudadLEHI
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal84043
Teléfono18014329000
Sitio Webhttps://www.lifevantage.com/
Símbolo de cotizaciónLFVN
Fecha de salida a bolsaSep 12, 2012
Director ejecutivoFife (Steven R)
Ejecutivos de LifeVantage Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Steven R. Fife, CPA
Mr. Steven R. Fife, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
644.90K
-1.27%
Mr. Darwin K. Lewis
Mr. Darwin K. Lewis
Independent Director
Independent Director
137.27K
+0.51%
Ms. Kristen Cunningham
Ms. Kristen Cunningham
Chief Sales Officer
Chief Sales Officer
128.30K
-1.50%
Mr. Michael A. Beindorff
Mr. Michael A. Beindorff
Independent Director
Independent Director
124.81K
+3.78%
Mr. Raymond B. (Ray) Greer
Mr. Raymond B. (Ray) Greer
Independent Chairman of the Board
Independent Chairman of the Board
112.82K
+11.99%
Ms. Alissa Neufeld
Ms. Alissa Neufeld
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
83.09K
-1.74%
Ms. Cynthia (Cindy) Latham
Ms. Cynthia (Cindy) Latham
Independent Director
Independent Director
64.88K
+20.86%
Mr. Carl Aure
Mr. Carl Aure
Chief Financial Officer
Chief Financial Officer
24.78K
-6.16%
Mr. Rajendran (Raj) Anbalagan
Mr. Rajendran (Raj) Anbalagan
Independent Director
Independent Director
24.00K
+56.38%
Ms. Julie Boyster
Ms. Julie Boyster
Chief Marketing Officer
Chief Marketing Officer
--
-100.00%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Steven R. Fife, CPA
Mr. Steven R. Fife, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
644.90K
-1.27%
Mr. Darwin K. Lewis
Mr. Darwin K. Lewis
Independent Director
Independent Director
137.27K
+0.51%
Ms. Kristen Cunningham
Ms. Kristen Cunningham
Chief Sales Officer
Chief Sales Officer
128.30K
-1.50%
Mr. Michael A. Beindorff
Mr. Michael A. Beindorff
Independent Director
Independent Director
124.81K
+3.78%
Mr. Raymond B. (Ray) Greer
Mr. Raymond B. (Ray) Greer
Independent Chairman of the Board
Independent Chairman of the Board
112.82K
+11.99%
Ms. Alissa Neufeld
Ms. Alissa Neufeld
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
83.09K
-1.74%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de LifeVantage Corp?
Los cinco principales accionistas de LifeVantage Corp son: Mr. Steven R. Fife, CPA
¿Cuántas instituciones poseen acciones de LifeVantage Corp (LFVN)?
A fecha de 2026Q1, 242 instituciones poseen acciones de LifeVantage Corp, con un valor de mercado combinado de aproximadamente 9.36M, lo que representa el 74.19% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -566760.00.